The BioHub - by Avetix

On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing.Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio.Tune in to hear more about how Gemma & the team identify investment opportunities & why they focus on early-stage investments in a market that has recently leaned toward late-stage de-risked assets.We also chat briefly through some potential pitfalls for founders looking for funding, their newest fund bridging healthcare & AI, and success stories from the Invivo Partners portfolio, including EsoBiotec.

Ahmet Tutuncu, a physician-scientist and CEO of AeroRx Therapeutics, shares his insights on innovative nebulized therapies for COPD. He discusses the development of AERO-007, the first nebulized LABA/LAMA duo, and AERO-111, a groundbreaking triple therapy. The conversation highlights the unique challenges of targeting older COPD patients who struggle with inhalers. Ahmet also explores the renewed investor interest in nebulized solutions following major deals in the industry, reflecting on the mission to improve patient outcomes.

On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023.Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibrotic diseases, the team are currently focused on patients with end-stage liver cirrhosis who otherwise only have transplantation as a treatment option.Tune in to hear more about Resolution's ongoing ph1/2 trials & what to look out for from them in 2026. We also discussed Amir's findings during the transition from big pharma to small biotech, plus the pro's & con's of building in biotech in The UK.

Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases.With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.

We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year. SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments. It was great to sit down with Miquel and hear about his journey in biotech & the origins of SpliceBio. He also shared some advice for other scientific co-founders stepping into the CEO-hotseat & his take on why Barcelona is well positioned to be the next EU biotech hot-spot.

We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub!Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member.At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies.We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.

Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences.Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia. Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies.In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management.Let’s get into it.

Lance Baldo, CEO of Beacon Therapeutics and seasoned biotech executive, shares insights from his impressive career in ophthalmology. He discusses the VISTA phase-3 trial of laru-zova, an AAV gene therapy for X-Linked Retinitis Pigmentosa, detailing its promising progress and expected results in 2026. Lance delves into the challenges of transitioning to CEO, and emphasizes the importance of team dynamics and regulatory strategies. His journey from medicine to biotech highlights his commitment to innovation and patient impact in treating blinding diseases.

Welcome to The BioHub Podcast.I’m joined by Luba Greenwood, CEO of Gallop.Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout.We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to cancer.It’s an inspiring and powerful conversation — let’s get intoit.

Christian Leisner, the CEO and co-founder of CDR Life, a biotech innovator in targeted T-cell immunotherapies, shares insights from his impressive career. He discusses the challenges of funding and intellectual property in biotech, and the exciting potential of CDR404, a promising T-cell engager designed for cancer treatment. Leisner also highlights the adaptability of their platform for autoimmune diseases, and the rapid advancements in oncology drug development. Plus, his choice of historical figures for dinner reveals his love for exploration and intellectual discourse.